Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,554 questions in 140 reviews · Heart
current versionsNo studies 272 · 17.5%Ungraded 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interleukin‐2 RA vs polyclonal antibody induction Cytomegalovirus infection Number of participants diagnosed with CMV infection · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 0.97 [0.53, 1.75] | 4 studies · 185 participants | Low |
Interleukin‐2 RA vs polyclonal antibody induction Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | no estimate extracted | 4 studies · 185 participants | Low |
Interleukin‐2 RA vs polyclonal antibody induction Cancer Number of participants diagnosed with cancer · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 9 [0.52, 156.91] | 4 studies · 185 participants | Low |
Monoclonal antibody vs polyclonal antibody Mortality Mortality at latest · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 1 [0.9, 1.1] | 7 studies · 315 participants | Low |
Monoclonal antibody vs polyclonal antibody Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 0.96 [0.67, 1.37] | 3 studies · 146 participants | Low |
Monoclonal antibody vs polyclonal antibody Infection Number of participants diagnosed with infection · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 1.12 [0.91, 1.39] | 5 studies · 214 participants | Low |
Monoclonal antibody vs polyclonal antibody Cytomegalovirus infection Number of participants diagnosed with CMV infection · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 1.32 [0.77, 2.28] | 4 studies · 201 participants | Low |
Monoclonal antibody vs polyclonal antibody Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 3.84 [0.45, 32.96] | 4 studies · 157 participants | Low |
Intervention NR Infection Number of participants diagnosed with infection · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 0.99 [0.79, 1.24] | 3 studies · 545 participants | Low |
Monoclonal antibody vs polyclonal antibody Cancer Number of participants diagnosed with cancer · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 2.19 [0.51, 9.43] | 4 studies · 157 participants | Low |
Intervention NR Cytomegalovirus infection Number of patients diagnosed with CMV infection · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 0.86 [0.63, 1.19] | 5 studies · 606 participants | Low |
Intervention NR Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 0.74 [0.14, 3.82] | 5 studies · 606 participants | Low |
Intervention NR Cancer Number of participants diagnosed with cancer · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 1.01 [0.45, 2.28] | 4 studies · 576 participants | Low |
Interleukin‐2 RA vs no induction Mortality Mortality at latest · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 1.53 [0.85, 2.76] | 4 studies · 576 participants | Low |
Interleukin‐2 RA vs no induction Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 0.73 [0.46, 1.17] | 4 studies · 576 participants | Low |
Interleukin‐2 RA vs no induction Infection Number of participants diagnosed with infection · heart transplant recipients Immunosuppressive T‐cell antibody induction for heart transplant recipients (2013) · Cochrane | RR 0.99 [0.79, 1.24] | 3 studies · 545 participants | Low |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) All‐cause death: not measured · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | no estimate extracted | NR | No studies |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo Restenosis Coronary angiography · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.52 [0.33, 0.8] | 2 studies · 432 participants | High |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo Recurrence angina pectoris with 1 month · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.31 [0.1, 0.92] | 1 study · 314 participants | High |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo Recurrence angina pectoris with 3 months' · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.37 [0.19, 0.71] | 1 study · 314 participants | High |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo Recurrence angina pectoris with 6 months' · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.26 [0.18, 0.38] | 2 studies · 432 participants | High |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo Health‐related quality of life: not measured · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | no estimate extracted | NR | No studies |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) Cardiac mortality · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | no estimate extracted | 2 studies · 190 participants | Moderate |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) Serious adverse events · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.47 [0.25, 0.9] | 1 study · 108 participants | High |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) Restenosis Coronary angiography · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.41 [0.22, 0.75] | 2 studies · 190 participants | High |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) Recurrence angina pectoris Treadmill exercise test · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.47 [0.3, 0.72] | 2 studies · 190 participants | Moderate |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) Health‐related quality of life: not measured · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | no estimate extracted | NR | No studies |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo All‐cause death: not measured · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | no estimate extracted | NR | No studies |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo Cardiac mortality · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | no estimate extracted | 2 studies · 432 participants | High |
Xiongshao capsule (XSC) plus conventional western medicine (CWM) vs conventional western medicine (CWM) plus placebo Serious adverse events · patients with restenosis after percutaneous coronary intervention in coronary heart disease Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease (2013) · Cochrane | RR 0.45 [0.28, 0.7] | 2 studies · 432 participants | High |
Face‐to‐face interventions vs control Cardio‐respiratory fitness: 12 months Sub maximal assessment of cardio‐respiratory fitness · patients with promoting physical activity Face‐to‐face interventions for promoting physical activity (2013) · Cochrane | no estimate extracted | 2 studies · 426 participants | Moderate |
Face‐to‐face interventions vs control Dichotomous outcomes: 12 months Self‐reported PA questionnaire · patients with promoting physical activity Face‐to‐face interventions for promoting physical activity (2013) · Cochrane | OR 1.58 [0.91, 2.75] | 3 studies · 3261 participants | High |
Face‐to‐face interventions vs control Dichotomous outcomes: 24 months Self‐reported PA questionnaire · patients with promoting physical activity Face‐to‐face interventions for promoting physical activity (2013) · Cochrane | OR 1.19 [1.02, 1.39] | 1 study · 2701 participants | High |
Face‐to‐face interventions vs control Self‐reported physical activity: 24 months Self‐reported PA questionnaire · patients with promoting physical activity Face‐to‐face interventions for promoting physical activity (2013) · Cochrane | no estimate extracted | 3 studies · 4235 participants | High |
Face‐to‐face interventions vs control Self‐reported physical activity: 12 months Self‐reported PA questionnaire · patients with promoting physical activity Face‐to‐face interventions for promoting physical activity (2013) · Cochrane | no estimate extracted | 8 studies · 23825 participants | Moderate |
Remote and web 2.0 vs control Cardio‐respiratory fitness: 12 months · patients with promoting physical activity Remote and web 2.0 interventions for promoting physical activity (2013) · Cochrane | no estimate extracted | 2 studies · 444 participants | High |
Remote and web 2.0 vs control Dichotomous outcomes: 12 months Self‐reported physical activity questionnaire · patients with promoting physical activity Remote and web 2.0 interventions for promoting physical activity (2013) · Cochrane | OR 1.42 [1.21, 1.66] | 1 study · 1089 participants | Moderate |
Remote and web 2.0 vs control Dichotomous outcomes: 24 months Self‐reported physical activity questionnaire · patients with promoting physical activity Remote and web 2.0 interventions for promoting physical activity (2013) · Cochrane | OR 1.27 [0.99, 1.63] | 1 study · 1088 participants | Moderate |
Remote and web 2.0 vs control Self‐reported physical activity: 24 months Self‐reported physical activity questionnaire · patients with promoting physical activity Remote and web 2.0 interventions for promoting physical activity (2013) · Cochrane | no estimate extracted | 1 study · 1049 participants | Moderate |
Remote and web 2.0 vs control Self‐reported physical activity: 12 months · patients with promoting physical activity Remote and web 2.0 interventions for promoting physical activity (2013) · Cochrane | no estimate extracted | 9 studies · 4547 participants | Moderate |
5 mg vs 10 mg All studies · patients with the initiation of oral anticoagulation Optimal loading dose of warfarin for the initiation of oral anticoagulation (2012) · Cochrane | RR 1.17 [0.77, 1.77] | 4 studies · 352 participants | Very low |
5 mg vs 10 mg Single INR measure · patients with the initiation of oral anticoagulation Optimal loading dose of warfarin for the initiation of oral anticoagulation (2012) · Cochrane | RR 1.49 [1.01, 2.21] | 2 studies · 250 participants | Very low |
5 mg vs 10 mg Consecutive INR measures · patients with the initiation of oral anticoagulation Optimal loading dose of warfarin for the initiation of oral anticoagulation (2012) · Cochrane | RR 0.86 [0.62, 1.19] | 2 studies · 102 participants | Very low |
Factor Xa inhibitors vs Anticoagulants All causes of mortality at 30 days · Anticoagulants in ACS Factor Xa inhibitors for acute coronary syndromes (2011) · Cochrane | RR 0.9 [0.8, 1.01] | 4 studies · 27976 participants | High |
Factor Xa inhibitors vs Anticoagulants All causes of mortality at 30 days ‐ UFH · Anticoagulants in ACS Factor Xa inhibitors for acute coronary syndromes (2011) · Cochrane | RR 0.98 [0.82, 1.18] | 2 studies · 6760 participants | High |
Factor Xa inhibitors vs Anticoagulants All causes of mortality at 30 days ‐ Enoxaparin · Anticoagulants in ACS Factor Xa inhibitors for acute coronary syndromes (2011) · Cochrane | RR 0.85 [0.73, 0.98] | 2 studies · 21216 participants | High |
Factor Xa inhibitors vs Anticoagulants Major bleeding at 30 days · Anticoagulants in ACS Factor Xa inhibitors for acute coronary syndromes (2011) · Cochrane | RR 1.01 [0.98, 1.04] | 2 studies · 20404 participants | High |
Factor Xa inhibitors vs Anticoagulants Major bleeding at 30 days ‐ UFH · Anticoagulants in ACS Factor Xa inhibitors for acute coronary syndromes (2011) · Cochrane | RR 0.98 [0.92, 1.04] | 1 study · 326 participants | High |
Factor Xa inhibitors vs Anticoagulants Major bleeding at 30 days ‐ Enoxaparin · Anticoagulants in ACS Factor Xa inhibitors for acute coronary syndromes (2011) · Cochrane | RR 1.02 [1.01, 1.02] | 1 study · 20078 participants | High |
Factor Xa inhibitors vs Anticoagulants Minor bleeding at 30 days · Anticoagulants in ACS Factor Xa inhibitors for acute coronary syndromes (2011) · Cochrane | RR 0.7 [0.14, 3.39] | 2 studies · 20404 participants | High |